Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.34 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23949014 | 0.96 | SLC6A5 (0.41) | SLC6A5MMP2CYP3A4KDM4AHIF1A | |
| SCHEMBL23925864 | 0.79 | CNR1 (0.31) | — | |
| SCHEMBL23948493 | 0.77 | SLC6A5 (0.46) | SLC6A5MMP2CYP3A4KDM4AHIF1A | |
| Acetic Acid SCHEMBL23925799 | 0.76 | SLC6A5 (0.39) | SLC6A5MMP2CYP3A4KDM4AHIF1A | |
| Oxalic Acid SCHEMBL23926047 | 0.76 | SLC6A5 (0.43) | SLC6A5MMP2CYP3A4KDM4AHIF1A | |
| Oxalic Acid SCHEMBL23926045 | 0.76 | SLC6A5 (0.43) | SLC6A5MMP2CYP3A4KDM4AHIF1A | |
| SCHEMBL23949017 | 0.72 | SLC6A5 (0.41) | SLC6A5MMP2CYP3A4KDM4AHIF1A | |
| Acetic Acid SCHEMBL30286865 | 0.69 | SLC6A5 (0.44) | SLC6A5MMP2CYP3A4KDM4AHIF1A | |
| Acetic Acid SCHEMBL2904259 | 0.68 | SLC6A5 (0.75) | SLC6A5PAOXKDM4E | |
| SCHEMBL23949016 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419963-B2 | Diels-Alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4135775-A1 | DIELS-ALDER CONJUGATION METHODS | Regeneron Pharmaceuticals, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20220378918-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS INC. (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2021211984-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | SLC6A5 844/4885MMP2 2241/4885CYP3A4 1943/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | SLC6A5 844/4885MMP2 2241/4885CYP3A4 1943/4885 |
| US-20220378918-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | SLC6A5 844/4885MMP2 2241/4885CYP3A4 1943/4885 |
| US-12419963-B2 | Diels-Alder conjugation methods | GLUL, TGM2, GLS | SLC6A5 844/4885MMP2 2241/4885CYP3A4 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.